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INTRODUCTION 
Postpartum hemorrhage is a major obstetrical emergency and one 
of the important but preventable causes of maternal morbidity and 
mortality.   It is often sudden, frequently unpredictable and catastrophic.  
Unless timely action is initiated, maternal death could occur in a short 
period.  It is the leading cause of maternal death in developing countries 
and ranks third or fourth cause in the developed countries.  Thus 
worldwide 1, 25,000 die due to postpartum hemorrhage  each year. (WHO 
1999) . Maternal mortality ratio in India during 2004 was 430/1,00,000 and 
the same in Tamil Nadu was 110/100,000. There were 1230 maternal 
deaths in Tamil Nadu out of which 21.6% was due to postpartum 
hemorrhage . 
The primary aim in the management of PPH should be its 
prevention (Chamberlain 1992).  Uterine atony remains the major cause of 
PPH.  Adequate contraction and retraction of uterus is essential for the 
prevention of postpartum hemorrhage . 
In modern obstetrics, active management is strongly recommended 
especially in women who are at risk of atony.  The drugs commonly used 
in  the active management of third  stage of labor are oxytocin, methyl 
ergometrine or their combination, syntometrine. 
Misoprostol, an analogue of PGE1 is an alternative in the  
prevention and management of PPH.  To date there has been few 
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prospective trials 1 and several randomized controlled trials comparing 
misoprostol with placebo2 or misoprostol with standard therapies, oxytocin 
and methylergometrine alone or in combination)3 for prevention of PPH.  It 
has also been reported to control PPH unresponsive to oxytocin and 
methylergometrine. 
Rectal misoprostol is an effective, easily administrable drug, which 
has shown, promises of being an efficacious drug in the management of 
PPH.  This drug has the added advantage that it can be safely 
administered even by paramedical personnel during referral of a mother 
with PPH to higher institutions. 
This preliminary study was undertaken to assess the efficacy of 
rectally administered misoprostol at a dose of 800ug in the  management 
of III stage of labor to prevent PPH and to analyze the  superiority or 
otherwise of intravenous  methylergometrine in the active management of 
third stage of labor with rectal misoprostol. 
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REVIEW OF LITERATURE 
The introduction of oxytocics for the management of PPH has 
contributed to a marked reduction in maternal mortality  from 1:3000  in 
1930s ; to 1:20,000 in 1950s ( Green hill, 1951)  and further  falling to  1 in 
60,000 in1980s. Uterine atony accounts for 80% of cases of PPH 
(Arulkumaran & Decruze, 1999)5 and hence most of the studies were 
concentrated on treating  this condition with  various drugs and methods. 
Prendiville et al in ‘Bristol third stage trial’6 found an incidence of 
postpartum bleeding of 5.9% in actively managed group and 17.9% in 
physiologically managed group.  They concluded that active management 
of third stage of labor  reduces the risk of PPH by 30-40%. 
Primary aim here is its prevention.  Active management of third 
stage of labor reduces the risk of PPH by 30-40% (Prendiville et.al, 1988)7 
Routine active management was shown to be superior to expectant 
management in that there was a statistically significant reduction in the 
amount of postpartum blood loss, postnatal blood transfusion, the need for 
therapeutic oxytocics and the duration of third stage.  These findings were 
confirmed in general population and also in women considered to be at 
risk of third stage complications (Prendivillie et al 2002)8 
For the  prophylactic and therapeutic management of PPH, various  
oxytocics were tried in different doses and routes like 
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• Oxytocin – 5 units  IV bolus. 
• Oxytocin 10-20 units IV drip 
• Methylergometrine 0.2mg IM/IV 
• 15- Methyl PG F2 ∝ 125-250mcg IM. 
• Latest in trials is misoprostol 
 
All the above drugs except misoprostol, need refrigeration to 
maintain its potency.  This facilities may not be available in developing 
countries at all times & places. 
Thus the search for a thermostable uterotonic has thrown light on 
misoprostol which is shown to be stable at room temperature and it has 
been evaluated for both the prevention  and the treatment of PPH. 
Randomized controlled trial by O’ Brien9 revealed the efficacy of 
misoprostol in the treatment of severe PPH. 14 women with continued 
uncontrolled blood loss unresponsive to standard oxytocics were given 
1000 ugm of misoprostol rectally and bleeding was found  to be arrested 
within 3 minutes of administration. 
Another randomized  controlled study comparing syntometrine with 
rectal administration of 400 mcg of misoprostol showed that the third stage 
duration, post partum blood loss, postpartum hemoglobin estimation were 
similar in both groups - (Bamingboye, Hofmeyr et al 1998).4 
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A descriptive study 10 carried out with 1000 ug of  misoprostol  in 41 
women with severe PPH unresponsive to oxytocics revealed control of 
hemorrhage  in 63% (26/41) of mothers within 10minutes   of 
administration. 
From the study conducted at Aim shams university, Cairo, 11 Egypt 
it was concluded that rectal misoprostol may be used safely in the 
management of the third stage of labor because estimated blood loss was 
lower with misoprostol group, duration of third stage was similar in both 
groups, and post partum hypertension occurred in oxytocin - methergine 
group. 
Randomized controlled trial 12 of rectal  misoprostol versus oxytocics 
in third stage management conducted in 240 parturient women at Toronto 
hospital concluded that the rectal misoprostol is of equivalent efficacy to 
potential oxytocics for the  prevention  of primary postpartum hemorrhage  
and rectal misoprostol is an appropriate uterotonic agent for routine 
management of third stage of labour.  The duration of third stage, blood 
loss, need for additional oxytocics were similar in both groups. 
Another study conducted at Division of Maternal and Fetal 
Medicine, Imperial College School of Medicine, London13 to characterize 
the pharmacokinetics and adverse effect profile of rectally administered 
misoprostol concluded that the mean maximum serum concentration of 
misoprostol of  144pg/ml was achieved on average of 23 minutes  later 
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than in oral group and the incidence  of shivering is significantly reduced in 
rectal group. 
Randomized controlled trial 14 comparing rectal misoprostol 600mcg 
with conventional oxytocics in the treatment of third stage of labor revealed 
that rectal misoprostol is significantly less effective than oxytocin plus 
methylergometrine for the prevention of PPH because the incidence of 
postpartum hemorrhage  was 9.8% in rectal misoprostol group compared 
with 3.5% in the group that received oxytocics and methylergometrine 
therapy.  Significantly more women needed additional oxytocics in the 
misoprostol group. 
Another descriptive study 15 conducted at Djibouti Army hospital 
showed that arrest  of hemorrhage   in PPH due to atony unresponsive to 
syntocinon occurs  within 5 minutes   of administration of rectal 
misoprostol. 
Cochrane database systemic review 2000 16 concluded that ‘active 
management is superior to expectant management’ in terms of blood loss, 
PPH and other serious complications  of third  stage.  It is however 
associated with an increased risk of unpleasant side effects and 
hypertension, where ergometrine is used.  Active management should be 
the routine management of choice for women expecting to deliver a baby 
in a maternity hospital. 
Gerstenfeld TS. Wing et al., (2001) 17  revealed that rectal 
misoprostol 400 mcg was no more effective than intravenous oxytocics in 
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prevention of postpartum hemorrhage . 
Cochrane database systemic review 2004 18 concluded that neither 
intramuscular prostaglandins nor misoprostol are preferable to 
conventional injectable uterotonics as part of active management of third  
stage of labor especially for low risk women. 
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POST PARTUM HEMORRHAGE  
Definition: Hemorrhage  occurring after the delivery of the fetus is 
termed as postpartum hemorrhage .  Primary PPH is defined as loss of 
500ml or more of blood per vaginum during the first 24hrs after the 
delivery of the baby or  even if  the blood loss is less than 500ml but 
associated with significant hemodynamic changes in the mother.  Massive 
postpartum hemorrhage  is defined as loss of greater than 1000 or 1500 
ml of blood. ACOG-defines PPH as blood loss which decreases the 
hematocrit by  10% or  needs a transfusion. 
The blood loss is often estimated visually.  The visual estimation 
underestimates the actual blood loss by 50% (Pritchard and associates 
1962) 25 .The problem of estimating the amount of blood loss accounts for 
the wide range of incidence of PPH quoted in literature, which varies from 
2-11% (Gilbert et al 1987, Hall et all 1985)26 . When quantitative 
measurements of blood loss are taken the incidence rises up to 20%  
(Newton et al 1961)27 . Life threatening hemorrhage  occurs in 1 in 1000 
deliveries (Lewis and Drife 1998).28 
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More than half of the maternal deaths occuring within 24hrs of 
delivery  are  mostly due to  PPH . 
Causes of PPH 
1. Uterine atony 
2. Genital  tract  trauma 
3. Coagulopathy 
4. Retained placenta 
5. Uterine inversion 
Normally the control of hemorrhage  following delivery is by 
contraction and retraction of myometrial  fibers. This causes kinking of 
blood vessels and so cuts off the blood flow to the placental site.  Failure 
of this mechanism resulting from disordered myometrial   function is called 
uterine atony and is the most common cause of PPH.  This complicates 
approximately 1 in 20 deliveries.   20% of women who develop uterine 
atony has no apparent risk factors for this condition.  Predisposing factors 
include 
• High parity 
• Uterine over distension  secondary to 
1. Multiple pregnancy 
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2. Hydramnios 
3. Fetal macrosomia 
• Prolonged labour 
• Precipitate labour 
• Antepartum hemorrhage  
• Retained placenta 
• Uterine abnormalities or fibroids 
• Previous history  of  PPH (risk of recurrence is 25%), manual 
removal of placenta. 
• General anaesthesia 
• Uterine inversion 
• Chorioamnionitis 
• Myometrial relaxants- MgSO4, B-agonists, diazoxide, 
halothane, calcium channel blockers. 
• Mismanagement of third stage by pulling the cord in an 
subcontracted uterus leads  to partial separation of placenta. 
• Anemia and 
• Operative vaginal delivery 
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Prophylactic management of PPH 
The aim in the management of PPH should be prediction & 
prevention. 
• Women at risk of PPH should be identified 
• On admission, blood should be taken up for full blood count, 
grouping and cross matching. 
• Wide bore cannula should be inserted for administration of ecbolics 
and fluids if needed. 
• Active management of third  stage of labor is recommended. (to all 
women) 
• Early sucking  ( breast feeding) 
Therapeutic Management of PPH 
It requires multidisciplinary team for optimum management.  It 
involves simultaneous resuscitation of the patient and identification of 
cause and instituting definitive treatment. 
Resuscitation: Quick assessment of 
 General condition 
 Blood loss  and 
 Call for assistance 
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1. Insert 2 large bore intravenous cannula & administration of  fluids 
(crystalloids/colloids) 
2. Nasal O2  6-8 liters of 100% oxygen through  mask. 
3. Catheterize the bladder. 
4. Transfusion of blood / blood products. 
5. Monitoring of vital parameters. 
To identify the cause: 
• Check the contractility of uterus. 
• Rule out   lower genital tract lacerations 
• Make sure the entirety  of placenta & membranes 
Definitive treatment: 
If  uterine atony  is the underlying cause,  then  vigorous uterine 
massage followed by bimanual compression is to be given. 
Medical methods should be instituted in a step wise manner 
followed by other surgical methods.   It one method  fails, other method 
should be tried, with minimum loss of time. 
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Clinical diagnosis 
Signs and symptoms are  related  to the  amount of blood loss. 
Class Blood loss BP change Signs & symptoms 
Class I 
(compensatory) 
10-15% 
500-1000ml 
None Tachycardia 
II 15-30% Slight fall in 
systolic BP 
Cold & clammy skin, weakness, 
tachycardia, postural 
hypotension, thirst, decreased 
pulse pressure, delayed 
capillary refilling time 
III 30-40%  Oliguria, restlessness 
confusion, , HR 120-160  
/minute 
RR 30-50 / minute 
IV > 40%  Anuria, collapse,  coma, death 
 
INVESTIGATION 
• Hemoglobin  % 
• Packed cell volume  
• Blood grouping & typing,  cross matching 
• Coagulation profile 
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Medical methods: 
1. Intravenous infusion of 20-40 units of  oxytocin in 1000ml normal 
saline. 
2. Intramuscular PG F2∝ - 250  mcg once in 15-90 minutes 
3. Rectal misoprostol 800 mcg. 
Surgical management: 
1. The tamponade test with  Senkstaken- Blackmore tube or Rusch 
balloon catheter. 
2. Laparotomy 
a) If bimanual  compression of uterus reduces  the bleeding,   
brace sutures  can be applied 
1. B- lynch sutures 
2.Multiple square sutures 
b) If the PPH follows placenta previa apply 
I. Isthmus- cervical apposition sutures 
II. Under suturing of placental  bed. 
c) If bimanual compression fails to control the bleeding 
following procedures to be undertaken. 
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Step wise  ligation of  blood vessels including 
1. Uterine artery 
2. Infundibulo pelvic vessels. 
3. Internal iliac artery ligation. 
d) Uterine artery embolization 
e) Hysterectomy – which  is the last resort. 
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THE THIRD STAGE OF LABOUR 
It commences with the delivery of the infant and ends with the 
delivery of the placenta. The mean length of  third stage of labor is 
6minutes   and the ninety seventh percentile is 30minutes  . 19 The 
duration of third stage is very important because direct relationship has 
been observed between the time interval and the risk of significant 
maternal morbidity. 
Physiology: 
After delivery of the infant, the uterine muscles contract and retract 
with a resultant reduction in the size of upper segment.  This shortening 
reduces the area of uterine surface to which the relatively incompressible 
placenta is attached.   Separation of placenta occurs through spongy layer 
and it is forced down towards the dilated lower uterine segment.  (Mac 
person and Wilson 1965).  The main uterotonic hormones responsible for 
uterine contraction are oxytocin and prostaglandin.20 
Normal volume of blood flow through the placenta at term is 700ml/ 
minute.21   This has to be arrested within seconds following placental 
separation.  Otherwise serious hemorrhage  will occur.  The three inter-
related physiological mechanisms responsible for the arrest of hemorrhage  
are 
1. Retraction of oblique muscle fibers in upper segment which 
acts as a ligature to the torn vessels that intervene through 
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the muscle. 
2. Following separation, the strong uterine contractions brings 
the uterine walls into apposition so that further pressure is 
exerted  on the placental site. 
3. There is transitory increase in  the  activation of the 
coagulation and fibrinolytic system around the placental site.  
So, clot formation in the torn vessels is intensified.  Placental 
site is covered by fibrin mesh utilizing  5-10% of the  
circulating fibrinogen. 
Any impairment in these mechanisms predisposes to severe  post 
partum hemorrhage . 
Mechanisms of placental separation: 
1.  Schultz mechanism: 
During the process of separation there is formation of retroplacental 
haematoma. First the central portion, later  the rest of the  placenta is 
delivered inversely.  So the fetal surface appears first with the 
membranes covering the maternal surface. 
2. Mathew Duncan mechanism: 
Edge of the placenta  separates first and  the maternal surface 
appears at the  vaginal outlet first. 
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Signs of placental separation: 
Because attempts to express the placenta prior to its separation are 
futile and possibly dangerous, it is important to recognize the following 
signs  of placental separation, which appear within about one minute  after 
delivery of the infant and usually within 5 minutes  . 
1. The uterus becomes globular and firm.  This is the earliest sign to 
appear. 
2. Sudden gush of blood. 
3. The uterus rises in the abdomen because, the placenta having 
separated, passes  down into the lower uterine segment and 
vagina, where its bulk pushes the uterus upward. 
4. Extra vulval lengthening of umbilical cord. 
Physiological or expectant management: 
As long as the uterus remains firm and there is no unusual 
bleeding, an attitude of watchful waiting until the placenta gets separated  
and  delivered by maternal efforts.  If the efforts fail to deliver the placenta, 
after ensuring the firm contraction of uterus, pressure is exerted with the 
hand on fundus to propel the detached placenta into the vagina.  It does 
not recommend uterotonics until after delivery of placenta (if at all) and not 
cord traction and cord is clamped after cessation of pulsation - Roger  J, 
Wood. J et al., 1998 22 
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Active management of  third stage  of labour 
It was first described by Thilaganathan & collegues,23 in 1993 and 
includes the following: 
2. Prophylactic use of oxytocics. 
3. Early clamping of cord 
4. Controlled cord traction 
Prophylactic use of oxytocics: 
Standard management is to administer oxytocics with the delivery 
of anterior shoulder in a vaginal delivery in cephalic presentation and 
following delivery of the head in vaginal breech delivery. The objectives of 
prophylactic oxytocics are: 
1. to ensure efficient contraction of the uterus, thus minimizing the 
amount of blood loss. 
2. To promote rapid and complete separation and the descent of the 
placenta. 
3. To be more effective, oxytocics should be given before the 
placental separation. 
Early clamping of cord: 
Active management of  third stage of labor entails the early 
clamping and dividing the umbilical cord before commencing controlled 
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cord traction. The duration of third  stage is reduced by early cord 
clamping ( Enkin et al, 1995).24 However the time of clamping  does not 
appear to influence the rate  of PPH. The efficacy of this intervention is 
however, questioned. 
Brandt- Andrew’s technique for the delivery of placenta: 
When the signs of placental separation has appeared, after 
ensuring the firm contraction of uterus, gentle but steady downward 
traction is applied to the cord and  at the same time countertraction is 
exerted over the  body of uterus in upward direction to prevent the  
inversion of uterus. 
Examination of the placenta 
The placenta should be examined after its removal for any missing 
cotyledons. If  it is there, then immediate exploration   is necessary. 
Abnormalities of the third stage 
• Retained placenta 
• Inversion  of uterus 
• Post partum hemorrhage . 
Any amount of stored blood cannot equate for a few ml of patient’s 
own blood. So adequate  management of third stage is crucial  for the 
prevention of post partum hemorrhage . 
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PHARMACOLOGY OF UTEROTONICS 
The primary mechanism by which hemostasis is  achieved at the 
site of placental separation  during the third stage of labor is compression 
of   blood vessels by well contracted myometrium.  The  following drugs 
are used in various ways to promote myometrial contractions ( Philips and 
Kinch 1994). They are given alone or in combination. 
1. oxytocin 
2. Methyl ergometrine 
3. Syntometrine 
Oxytocin: 
• The synthetic form of the octapeptide of oxytocin is 
commercially available as syntocinon or pitocin. 
• It is not effective by mouth. 
• The half life of intravenous oxytocin is 3-5 minutes  . 
• Onset of action: Intravenous dose: within 30 –40 seconds 
         Intramuscular dose: after 3 minutes  . 
• Mechanism of action: It increases the frequency and strength 
of uterine contraction and augments retraction of uterus. 
• No absolute contraindications for its use. 
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• Deleterious effects can occur with inadvertent use of 
intravenous oxytocics. 
1. In  utero death of fetus 
2. Rupture of uterus 
• Side effects: 
1. Maternal hypotension 
2. Cardiac arrhythmias 
3. Water intoxication 
• Water intoxication occurs  when the rate of infusion is more 
than 40mU/mt and oxytocin is administered in large volume 
of electrolyte free solution (Whally and pritchand 1963).29 
• It should not be given intravenously as a large bolus but 
rather as a much more dilute solution by continuous 
intravenous infusion. 
• When oxytocin is to be administered in high doses for a 
considerable period of time,  it should be used either in 
normal saline or ringer lactate solution. 
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Ergometrine and methyl ergometrine: 
• It is an alkaloid obtained from ergot, a fungus that grows in rye  
and some other grains or it is synthesized from lysergic acid. 
• Mechanism of  action: causes tetanic  contraction of uterus 
• Onset of action: Intravenous dose: 30-40 seconds 
Intramuscular dose: 7 minutes 
• Maximum dose: 5 doses, total  of 1 mg. 
• It requires storage  at 2 to 8o C and must be protected from  
light.30 
• Ergometrine loses 90% of its potency after 1 year of storage 
at 21oC to 25oC 31 
Side effects 
• Nausea, vomiting, dizziness 
• Headache 
• Transient but severe hypertension rarely 
• Intracerebral hemorrhage  
• Myocardial infarction 
• Cardiac arrest 
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• Postpartum eclampsia 
• Pulmonary edema 
• Paraesthesia, tingling, numbness,  frank gangrene. 
Contraindications: 
Absolute: 
Before the third  stage of labour 
Relative: 
Liver disease 
Heart disease 
Hypertension 
Vascular  disorders 
Renal disease 
Syntometrine: 
• Combination of 5 units of oxytocin with 0.5mg ergometrine. 
• It is given intramuscularly. 
• Hypertension is not a significant problem with it. 
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Time taken by various drugs to act and their mode of action can be 
summarized as follows: 
Drug Onset of action Mode of action 
Oxytocin           IM 
3 minutes Induces  rhythmic 
contraction and augments 
retraction 
Ergometrine     IM 
                         IV 
7 minutes 
20-40 sec 
More prolonged tetanic 
contraction 
Syntometrine    IM 
2 minutes Minimal maternal side 
effects 
PG F2 α            IM 
5 minutes Myometrial contraction 
vasoconstriction. 
Though  prophylactic methyl ergometrine has its own advantage of 
reducing the post partum  blood loss its major disadvantage is transient  
but severe hypertension.  However evidence32 suggests  that the benefits 
of routine oxytocin administration outweigh the less likely risks. 
Mitchell and Elbourne et al 1993 33 found Intramuscular  
syntometrine to be more effective than oxytocin alone in the prevention of 
postpartum hemorrhage . 
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PHARMACOLOGY OF MISOPROSTOL 
Introduction: 
Prostaglandin was the name given by Von Euler in 1935 to a 
substance found in extracts and secretions from the human prostate and 
seminal vesicles. They are derived from arachidonic acid. 
Chemistry 
Prostaglandin (PG) are 20 carbon atom polyunsaturated fatty acids 
with  a five  membered cyclopentane ring and two side chains.  Depending 
upon the structure of the carbon ring, PGs are named A to I.  PGE1, E2, E3 
are named according to the number of double bonds respectively. 
The chemical formula of misoprostol is C22 H38O5 
0 
CH2 (CH2) 5 COOCH3 
 
H          CH3 
|  | 
 
OH   C= C-CH2 –C  (CH2)3 CH3 
 
Mechanism of action: 
1. It binds to both E2 and E3 prostanoid receptors and stimulates 
myometrial contraction. 
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2. It exerts a protective effect on the gastro intestinal mucosa by 
increasing mucus and bicarbonate ion secretion and it also inhibits 
acid secretion. 
Characteristics of misoprostol 
Misoprostol 
• Is inexpensive 
• Is easily stored (shelf-life- 3 years) 
• Has a minimal effect on cardiovascular and bronchial smooth 
muscle and hence can  be used in hypertensive and asthmatic 
patients. 
• Available as 100mcg and 200mcg tablets. 
• Route of administration - oral, vaginal, rectal, sublingual. 
• Stable at room temperature. So no need for refrigeration. 
Pharmacokinetics 
The exact time of onset, peak and duration of action following the 
administration of misoprostol rectally have not been studied in detail so far.  
But various clinical studies 9,10 have shown that arrest of hemorrhage  
occurs within 3-10minutes   of rectal administration of 800-1000ug of 
misoprostol in PPH patients. 
• Following the absorption, it is de-esterified and converted to its 
active pharmacological form misoprostol acid, which is responsible 
for various clinical activities. 
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• Primary site of metabolism of this drug is in liver and less than 1% 
is excreted in urine. So dose has to be adjusted in patients with liver 
disease.34 Since presystemic hepatic metabolism does not occur  
with rectal  administration there is  greater  bioavailability  and less 
side effects. 
• This drug has no known drug interaction. 
Side effects: 
• Nausea 
• Vomiting 
• Headache 
• Diarrhoea 
• Uterine cramps 
• Shivering 
• Pyrexia 
Gastrointestinal side effects are more with oral 
administration.  Most common side effects with rectal administration 
are pyrexia and shivering . 
Contraindications: 
Absolute:  Hypersensitivity 
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Relative: 
• Cardiovascular disease 
• Liver disease 
• Bronchial asthma 
• Hypertension 
• Renal disease 
• Convulsive disorders 
• Prior uterine surgery. 
Other uses of misoprostol 
• Cervical ripening and induction of  labour 
• First and second  trimester abortion 
• Treatment of peptic ulcer. 
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AIM OF THE STUDY 
 
To determine the effectiveness  and safety of misoprostol 
administered  rectally for the prevention of PPH. 
 
To compare the efficacy of rectal misoprostol with the  intravenous 
methyl ergometrine  in reducing the blood loss during the third stage of 
labor in  mothers at risk for PPH.  
 36
MATERIALS AND METHODS 
This randomized prospective comparative study was carried 
out at Govt.  Kasturba Gandhi Hospital, Madras Medical College, 
Chennai, during the period of  October 2004 to August 2005 on 
hundred   patients  who were admitted   to labor ward with  any of 
the  risk factors for PPH.  All the patients included in the study had 
vaginal delivery. 
The  patients   were assigned  into two groups: 
Group I:  Includes fifty patients in whom prophylactic methyl 
(Control)  ergometrine was used intravenously as  part of the 
active management    of labor. 
Group II:   includes fifty  patients in whom 800 mcg of  
misoprostol 
(Study) was kept rectally immediately after delivery of anterior 
shoulder. 
Inclusion criteria: 
Following were the inclusion criteria on the basis of which the 
patients were included in the study: 
• Overdistended uterus as in big baby, multiple pregnancy  
hydramnios. 
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• Prolonged labour 
• High parity (5 and above) 
• Abruptio placenta 
• Precipitate labour 
• Chorioamnionitis 
• Prolonged use of oxytocin 
• Previous history of  PPH 
• Where vaginal or instrumental  delivery is not contra indicated 
Exclusion Criteria: 
Patients with following risk factors were excluded from the study. 
• Heart disease 
• Epilepsy 
• Severe anemia 
• Traumatic PPH 
• Hepatic disorders 
• Disorders of blood coagulation 
• Previous scarred uterus 
• Where vaginal delivery is not contemplated 
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Procedure of drug administration 
In group I  0.2 mg of methyl ergometrine  was administered  intravenously 
soon after  delivery of the anterior shoulder of the baby.  
In group II ,  four  200 mcg of misoprostol tablets soaked in saline were 
kept rectally  soon after delivery of the  anterior shoulder of the baby.  
Estimation of blood loss: 
Immediately after delivery of the baby when all liquor was drained 
out, the patient was brought to the edge of the table where an inflated 
kelley’s pad was kept ready to be placed under the patient’s gluteal  
region. The lower end of pad was inserted into a measuring jug of  2 litre 
capacity with  every 20ml graduations.  The blood, which escapes per 
vaginum, gets collected in the jug.  After 20-30 minutes  , the clots in the 
jug was weighed separately and added to the amount of blood in the jug.  
The average  immeasurable blood loss due to episiotomy was taken as 
50ml (from the average calculated from normal vaginal delivery with 
episiotomy) and the same is not included in the blood loss calculated. 
Similarly, when there was profuse bleeding following episiotomy, such 
patients were excluded from the study. 
The following factors were noted in all patients: 
1. Time taken for the delivery of placenta from the time of 
administration of prophylactic methyl ergometrine in group-I and the 
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rectal administration of misoprostol in group II 
2. The amount of blood loss. 
3. The blood pressure measurements taken 5minutes   after the drug 
administration. 
4. Any complications. 
5. Side effects of drugs ( if any) – noted 
6. Need for  medical  / surgical  interventions and blood transfusion. 
7. Difference in antepartum  and the  post partum  hemoglobin levels 
measured  48 hrs after delivery. 
All these factors were compared between the two groups. 
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RESULTS 
This study was carried out at Govt Kasturba Gandhi Hospital, 
during the period of October  2004 – August 2005. 100 women were 
included in this study and the outcome analyzed using various parameters. 
The results are subjected to statistical analysis using the t test and chi- 
square test. 
Table I – Age distribution n=100 
Group I Group  II 
S.no Age No.of 
cases % 
No.of 
cases % 
1. <20 3 6% 5 10 
2. 20-25 25 50% 19 38 
3. 26-30 17 34% 21 42 
4. 30-35 4 8% 5 10 
5. >35 1 2%   
• Most of the patients in both the control and study group were in the 
age group of 20-30 years. (80-84%) 
• 6% cases in control group and 10% cases in study group were in 
the age group of less than 20 years. 
• Only 1 case (2%) in control group was above 35 years. 
• Youngest in this study was 18 years old and eldest was 37 years 
old. 
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Table II Booking status               n=100 
Group I Group II 
S.no Booking status No. of 
cases % 
No. of 
cases % 
1. Booked 50 100% 49 98 
2. Un Booked - - 1 2% 
• All of the patients except one in study group were booked cases 
though they were selected at random basis. 
 
 
Table III  Socio economic status          n=100 
Group I Group II 
S.No Socio economic status No. of cases % No. of cases % 
1. I     
2. II     
3. III     
4. IV 6 12% 8 16% 
5. V 44 88% 42 84% 
• 88% of cases in control group and 84% of study group  were 
belonged to class V socio economic status. 
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Table IV  - Distribution of gravidity             n=100 
Group I Group II 
S.No Gravida No. of 
cases % 
No. of 
cases % 
1. G1 15 30 18 36 
2. G2 22 44 20 40 
3. G3 7 14 8 16 
4. G4 4 8 3 6 
5. 5 above 2 4 1 2 
• 44% of cases in control group and 40% of cases in study group 
were second  gravida. 
• 30% of cases in control group and 36% of cases in study group 
were primigravida. 
• 2 cases in control group and, 1 case in study group were grand 
multipara. 
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Table V – Risk factors     n=100 
Group I Group II 
S.No Risk factors No. of 
cases % 
No. of 
cases % 
1. Over distended uterus
a. Big baby 
b. Hydramnios 
c. Multiple pregnancy
28 
18 
4 
6 
56% 29 
17 
5 
7 
58% 
2. Prolonged  labour 20 40 17 34 
3. Abruptio placenta   3 6 
4. Grand multi 2 4 1 2 
 
 
• 56% of cases in control group and 58% of cases in  study  group 
had over distended uterus in the form of either fetal macrosomia, 
hydramnios or multiple pregnancy. 
• 40% of cases in control group and  34% of cases in study group 
had prolonged  labor. 
• 3 cases of abruption  were included in study group. 
• 2 cases in control group and 1 case in study group were grand 
multipara. 
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Table VI – Onset of labor               n=100 
Group I Group II 
S.No Onset of labour No. of 
cases % 
No. of 
cases % 
1. Spontaneous 38 76 32 64 
2. ARM  & oxytocin 7 14 12 24 
3. PGE2 alone 3 6 3 6 
4. PGE2  + oxytocin 2 4 3 6 
 
 
• 76% of cases in control group and 64% of cases in study group had 
spontaneous onset of  labor. 
• In 14% of cases in control group and 24% of cases in study group, 
labor was induced with ARM  and oxytocin. 
• In 6% of cases in control group and 6% of cases in study group, 
labor was induced with PGE2 gel alone. 
• In 4% of cases in control group and 6% of cases in study group, 
labor was induced with both PGE2 gel and oxytocin. 
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Table VII – Nature of delivery         n=100 
Group I Group II 
S.No Nature of delivery No. of 
cases % 
No. of 
cases % 
1. LN 19 38 23 46 
2. LN  with  episiotomy / LPIIo 27 54 20 40 
3. Vacuum 1 2 5 10 
4. Forceps 3 6 2 4 
 
 
• 38% of cases in control group and 46% of cases in study group had 
normal vaginal delivery. 
• 54% of cases in control group and 40% of cases in study group  
were delivered by labor natural with episiotomy  or perineal 
lacerations of II°. 
• 8% of cases in control group and 14% of cases in study group had 
assisted vaginal delivery either vacuum extraction or forceps. In all 
these patients, traumatic PPH had been ruled out. 
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Table VIII – Duration of III stage of labor         n=100 
Group I Group II 
S.No Duration of  III stage (in minutes) No. of 
cases % 
No. of 
cases % 
1. < 2 15 30 2 4 
2. 2 – 4 30 60 23 46 
3. 4 – 6 4 8 19 38 
4. 6 – 8 - - 6 12 
5. >8 1 2 - - 
• In 90% of cases in control group, the duration of third stage of labor 
was less than 4 minutes  , whereas in study group only in 50% of 
cases the duration of  third stage of labor was less than 4 minutes  . 
• In significant number of cases in study group (50%) the duration of 
third stage was more than 4 minutes  . 
Table IX Comparison between duration of III stage of labor in both the 
groups              n=100 
S.No Group No. of cases 
Mean 
duration 
in 
minutes
SD ‘t’ value 
P 
value 
1. I 50 3.25 2.633 
2. II 50 4.5 1.446 
2.943 0.01 
• Mean duration of  third stage of labor in control group was  3.25 
minutes and in study group  it was 4.5 minutes. 
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• The difference in the mean duration of  third stage of labor between 
control and study group was 1.25 minutes  . which is not statistically 
significant (p=0.01). 
Table X – Amount of blood Loss                 n=100 
Group I Group II 
S.No Amount of blood         loss in ml No. of 
cases % 
No. of 
cases % 
1. <100 ml 3 6 - - 
2. 100 – 200 25 50 6 12 
3. 200 – 300 15 30 19 38 
4. 300 – 400 3 6 16 32 
5. 400 – 500 2 4 5 10 
6. >500 – 1000 1 2 4 8 
7. >1000 1 2 - - 
• Only 6% cases in control group had blood loss of less than 100ml.  
All the patients in study group had blood loss of more than 100ml. 
• 50 % cases in control group had blood loss in the range of 100 – 
200ml. 
• 38% of cases in study group had blood loss in the range of 200 – 
300ml. 
• 8% of cases in study group had blood loss of more than 500ml, 
which is significant. 
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• Only 4% of cases  in control  group had blood  loss of more than 
500ml. 
• One case in control group had severe postpartum hemorrhage  of 
about 1400ml. 
Table XI – Risk factors         n=100 
Group I Group II 
S.No Risk factors 
Blood loss in ml Blood loss in ml 
1. Over distended uterus 191.78 286.20 
2. Prolonged labor 315 361.17 
3. Abruption - 350 
4. Grand  multi 150 220 
• Mean blood loss in cases with overdistended uterus in control group 
was 191.78 ml, whereas in study group it was 286.2 ml. 
• Mean blood loss in  cases with prolonged  labor in the control group 
was 315 ml and  it was 361.17ml in study group . 
• 3 cases in study group with abruption had average blood loss of 
350ml. 
• In cases of grand multipara, the mean blood loss in control group 
was 150ml and in the study group was 220ml. 
• There was  significantly  increased  blood loss in study group when 
compared to the control group. 
 49
• Among all the risk factors, patients with prolonged labor had 
significantly increased blood loss. 
Table XII: Blood loss statistical analysis           n=100 
S.No Group No. of cases Mean in ml 
Standard 
Deviation
‘t’ 
value 
P 
value 
1. I 50 241.4 191.19 
2. II 50 315.44 111.35 
2.366 0.05 
 
• The difference in mean blood loss between the study and control 
group was 74 ml. 
• Though, the mean blood loss of 74 ml is high in study group, it is 
not statistically significant. 
• Intravenous methyl  ergometrine  is  superior  to  rectal misoprostol 
in  reducing  the third  stage blood loss. 
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Table XIII – Analysis of complications                n=100 
S.No Group PPH % 
1. I 2 4% 
2. II 4 8 
• In this study, the incidence of post partum hemorrhage  was 8% in 
study group,  compared to only 4% in control group. 
• One case in the control group had severe postpartum hemorrhage . 
Table XIV – Interventions  and Blood transfusion n=100 
Group I Group II 
 
S.No Interventions 
No. of 
cases 
% No. of 
cases % 
1. 
Medical 
 
2 4 6 12 
2. 
Surgical 
 
1 2 - - 
3. Blood transfusion 1 2 1 2 
• 12% of cases in the study group required additional oxytocics for 
the control of bleeding, whereas only 4% of cases in the control 
group required additional oxytocics either in the form of 10-20U of 
oxytocin infusion or PGF2∝ 250mcg IM. 
• One case in the control group had severe  PPH and required 5 units 
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of blood. Subsequently, she  had undergone subtotal hysterectomy 
as the bleeding was not controlled with other medical methods. 
• One case  in study group required one unit of blood for treatment of 
anemia. 
Table XV -  Side effects       n=100 
Group I Group II 
S.No Side effects 
No. of cases % No. of cases % 
1. Increase in BP 8 16 0 0 
2. Pyrexia - - 7 14 
3. Shivering - - 10 20 
4. Nausea 6 12 2 4 
5. Vomiting 2 4 - - 
 
• Most common side effect noted (16%) in control group  was 
significant increase in blood pressure (10 – 20mm of Hg either 
systolic or diastolic or both) 
• 12% of cases in control group  had nausea and 4% of cases in 
study group had vomiting. 
• Most common side effect in study group was shivering noted in 
20% of cases. 
• 14% of cases in study group had increase in body temperature, but 
not exceeding 100°C. 
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Table XVI  - Hemoglobin  difference       n=100 
Group I Group II 
S.No 
Hemoglobin 
difference           
in gm % No. of cases % No. of Cases % 
1. <0.5 39 78 19 38 
2. 0.6-1 7 14 23 46 
3. 1.1 – 1.5 3 6 6 12 
4. 1.6 – 2 0 0 2 4 
5. >2 1 2 0 0 
 
• Hemoglobin difference of  less than 0.5%  was noted in 78% of 
control group  and 38% of  study group. 
• Hemoglobin difference of 0.5 to 1gm% was noted in 14 % of cases 
in control group and 46% of cases in study group. 
• Hemoglobin difference of 1.6 –2gm% was noted in 4% of cases in 
study group. 
• One case in control group  had severe atonic PPH and the 
hemoglobin difference of more than 2 gm%  was noted in  her. 
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Table XVII: Hemoglobin difference statistical analysis   n=100 
S.No Group 
Mean hemoglobin
(gm %) 
SD 
T 
value 
‘P’ 
value 
1. I 0.53 .702
2. II 0.84 .456
0.653 
 
0.01 
 
• Mean hemoglobin difference in control group was 0.53gm% 
• Mean hemoglobin difference in study group was 0.84  gm% 
• Mean hemoglobin difference between study group and control 
group was 0.3 gm%, which is not statistically significant. 
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DISCUSSION 
This randomized prospective “Comparative study of efficacy of 
rectal misoprostol with intravenous  methyl ergometrine in the prevention 
of PPH in at risk PPH mothers” was undertaken in  hundred  patients , who 
had any of the risk factors for PPH. 
The results of this study were discussed as follows. 
 Most of the patients in this study were in the age group of 20-30 
years  (80-84%) 
 Though patients were selected at random basis, 99% of patients 
were booked cases 
 86% of  patients  in this study were belonged to class V socio 
economic status. 
 33%  cases were primigravidae and 42% cases were second 
gravidae and  only 3% cases were  grand multipara. 
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 57% of cases in this study had  overdistended uterus as  a risk 
factor (big baby 35%, hydramnios 10%, multiple pregnancy 13%). 
37% of cases had the prolonged labor(II stage) as a risk factor . 
 According to various literature,  
20% of women have no risk factors for PPH (Varner,M et al).35 
PPH was reported to occur in 6-22% of twin deliveries (Newton 
1986)36. 
Recurrence of PPH is 25% (Dewhurst, CJ et al)37 
 70% cases in this study group had spontaneous onset of 
labor and in 30% cases, labor was  induced  with either 
ARM & oxytocin , PGE2 gel  alone or PGE2 gel with 
oxytocin. 
 89% cases in this study had normal vaginal delivery and 
11% of cases had instrumental vaginal delivery (6% 
vacuum, 5% forceps). Incidence of atonic PPH was 7.3 in 
vacuum and 12.5% in forceps deliveries (Williams et al 
1981)38 
 In 90%  cases in control group, and 50% cases in study 
group  the duration of third stage was less than 4 minutes  .
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 The mean duration of  third  stage of labor in control group 
was 3.25 minutes   and in study group was 4.5 minutes   . 
The difference in the mean duration of third stage of labor 
between  the control and  study group was  1.25 minutes  
which is  not statistically significant and  this study well 
correlates with the study conducted  by Bamigboy et all in 
490 low risk women comparing the effectiveness  of 
syntometrine and 400 mcg of rectal  misoprostol  which 
showed no difference in the  duration of  third stage of 
labor. 
 56% of cases in group I and only 12% of cases in group II 
had blood loss of less than 200 ml. 50% of cases in study 
group had blood loss of 200-400 ml which is significant. So 
rectal misoprostol is less effective  in reducing  the third 
stage blood loss when compared to  intravenous methyl 
ergometrine. 
 The mean blood loss is relatively high in both the groups 
who had prolonged II stage when compared to  other  risk 
factor 
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 The mean  blood loss in control  group was 241.4ml and 
the mean blood loss in study group was 315.4ml. Though 
clinically the mean blood  loss of about 74.8ml was 
significantly high with rectal misoprostol, it is not 
statistically significant 
 Arulkumaran and  associates, 2004 concluded that oral   / 
rectal misoprostol was less effective  than conventional 
oxytocics.  Until alternative regimes of misoprostol are 
studied in large controlled trials, misoprostol is not 
recommended for routine  use  in third stage of labor. 
 In this study the incidence of postpartum hemorrhage  was  
4% in control group   and 8% in study group which 
correlates with  a following study. 
In a randomized controlled  study comparing  the 
effectiveness of parenteral oxytocics and  rectal 
misoprostol, the incidence  of postpartum  hemorrhage  
was 9.8% with rectal misoprostol group and only 3.5 % in 
the  group who received parenteral oxytocics  either 
oxytocin  or methyl ergometrine  therapy. 
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 4% of  cases in control group and 12% of cases in study 
group required additional oxytocics in the  form of either 
10-20U of oxytocin infusion or PGF2 ∝ 250 mcg IM, which 
differs slightly from the following  study. 
 Significantly more women needed additional oxytocics in 
the  group that received only rectal misoprostol therapy 
when compared with the group that received oxytocin  and 
ergometrine therapy (8.3% Vs 2.2%) - Caliskan E et al.14  
Gerstenfeld TS et al compared the rectally administered 
200 mg misoprostol to intravenously administered oxytocin 
for the management   of third  stage of labor. In this  study 
23%  of misoprostol group and 11% of oxytocin group were 
required  at least one additional  agent to  control the 
bleeding. 
 One patient  in control group  had   severe atonic PPH.  As 
the bleeding was not controlled with other medical 
methods, being the multipara subtotal hysterectomy was  
done.  She had    prolonged second stage as a risk factor 
for PPH.  3 units of blood transfused preoperatively and 2 
units of blood transfused postoperatively to this patient. 
 One case in  study group required one unit of blood for 
anemia 
 59
 Postpartum  hypertension is the most common side effect 
noted in control group (16%) 
Chong YS. Su LL, Arulkumaran S et al., 2004 – Active 
management of  third stage of labor though it is superior to 
expectant management  in terms of blood loss and 
postpartum hemorrhage , it is associated  with unpleasant 
side effects and hypertension when ergometrine is used. 
Most common side effects noted in study group were 
shivering (20%) and pyrexia (14%) 
Cochrane database systemic review  2001 – Shivering 
and elevated body temperature (>38°C) are the main side 
effects of misoprostol and are dose  related. 
Khan RU,  El Refaey H et al. 2003 - Misoprostol 
administered  rectally is associated with less  adverse 
effects compared to  oral misoprostol group . Incidence  of 
severe shivering was significantly reduced by 72%. 
 Hemoglobin difference of  less than 1gm%  was noted in 
92%  of cases in control group and 84% of cases in  study 
group. 
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 Mean hemoglobin difference  was 0.53 gm% and 0.84gm% 
in control and study group respectively . The difference 
between these 2 groups was 0.31gm% which does not 
have any statistical significance. 
 Karkanis SG associates, 2002 - No difference in 
hemoglobin was observed between the 400 mcg rectal 
misoprostol group (0.16 gm%) and the parenteral oxytocin  
group 0.14gm% 
From  this study, rectal misoprostol was found to be less effective  
in reducing the postpartum blood loss. 
Viller and collegues  2002 reviewed prophylactic use of misoprostol 
to prevent  postpartum hemorrhage and  concluded that oxytocin or 
oxytocin – ergot prepartions are more effective. 
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SUMMARY 
This present prospective study “Comparative study of efficacy of 
rectal misoprostol versus intravenous  methylergometrine in the prevention 
of PPH in at risk PPH mothers” was carried out at Govt. Kasturba Gandhi 
Hospital Madras Medical College, Chennai during the period October 2004 
– August 2005. 
Total of hundred cases who had any of the risk factors for PPH 
were included in the study. 
Group I 
Included fifty patients in whom intravenous methyl ergometrine was 
administered following delivery of anterior shoulder. 
Group II 
Included fifty  patients in whom, 800 mcg of misoprostol was kept 
rectally following delivery of the anterior  shoulders. 
The efficacy of prophylactic intravenous methyl ergometrine, and 
rectal misroprostal in reducing the postpartum blood loss were compared 
in  terms of duration of third stage, amount of blood loss, need for 
additional oxytocic therapy and change in prenatal and postnatal 
hemoglobin level in gm % and  the results were statistically analyzed. 
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Observations of this study includes, 
¾ Most of the patients were in the age group of 20-30 years. 
¾ 99% of cases were booked and most of the patients were belonged 
to class V socio-economic status. 
¾ 42% of cases were second gravida 33% of cases were primigravida 
and 3 case were grand multipara. 
¾ 54% of cases had overdistended uterus and 37% of cases had 
prolonged labor as the risk factor for PPH. 
¾ 70% of cases had spontaneous onset of labor and in remaining 
30% of cases labor was induced with either ARM & oxytocin,  PGE2 
gel alone or PGE2 with oxytocin. 
¾ 47% of  patients were delivered by labor natural with episiotomy or 
perineal laceration of IIo. 11% of cases had operative vaginal 
delivery either vacuum extraction or forceps delivery in whom 
traumatic PPH had been ruled out. 
¾ The duration of third  stage in 90% of cases in control group was 
less than 4minutes  , and only in 50% of cases in study group it 
was less than  4 minutes  . 
¾ The difference in the mean duration of third stage of labor between 
the two group was 1.25 minutes  . 
¾ 56% of cases in control group had blood loss of lessthan 200ml. 
Only 12% of cases in study group had blood loss of lessthan200ml. 
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70% of cases in study group had blood loss of 200 - 400ml. 
¾ Prolonged labor is associated with  significantly increased blood 
loss, when compared to other risk factors. 
¾ The difference in mean blood loss between the two groups was            
74ml. Comparing the absolute blood loss,  parenteral methyl 
ergometrine  appears to be  more effective than rectal misoprostol 
in reducing  postpartum blood loss. 
¾ Incidence of PPH was 8% in study group as compared to only 4% 
in control group. 
¾ 12% cases in study  and 4% cases in control  group  required  
additional parenteral oxytocic drugs.   
¾ The major side effects noted in study group were pyrexia (14%)  
and shivering (20%) 
¾ Common side effect noted in control group was increase in blood 
pressure. (16%) 
¾ Hemoglobin difference of less than 1gm% was noted in 92%  of 
cases in control group and 84% of cases in study group. 
¾ Mean hemoglobin difference between control and study group was 
0.31gm%, which has  no statistical significance. 
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CONCLUSION 
 Active management of third stage of  labor should be the 
routine management of choice for women expecting to 
deliver a baby by vaginal route in a maternity  hospital. 
 Rectal misoprostol is less effective than intravenous methyl 
ergometrine  as part of the active management of third stage 
of labor for prevention of postpartum hemorrhage . 
 Misoprostol need not replace oxytocin or ergometrine for 
prophylaxis in hospitals where these drugs could be properly 
stored. 
 Misoprostol is a very valuable drug in the armamentarium of 
doctors in rural setting and especially  midwives, who work in 
the periphery in developing countries, where these 
parenteral drugs could not be stored at the desired 
temperature and where parenteral drugs are impractical to 
administer or simply not available. 
 In above situations, misoprostol which is inexpensive, thermo 
stable with good safety profile  will have clear advantages 
over other conventional  injectable  oxytocics like methyl 
ergometrine . 
 This drug can be safely administered even by paramedical 
personnel while referring a mother with PPH to higher 
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institutions. 
 So, misoprostol deserves a special place in every pharmacy, 
health post and midwifery list and has considerable potential 
to reduce the maternal mortality from postpartum 
hemorrhage  in developing countries. 
So, in countries with high maternal mortality and limited resources, 
introducing low cost, evidence based practices that prevent PPH is an 
important way to improve women’s health. 
***********
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PROFORMA 
 
“COMPARATIVE STUDY OF EFFICACY OF RECTAL MISOPROSTOL 
VERSUS INTRAVENOUS METHYLERGOMETRINE   IN THE 
PREVENTION OF PPH IN AT RISK PPH MOTHERS ” 
 
 
Name:  Age   Unit   IP No. 
 
Socioeconomic  status  Married:  Booked / Unbooked 
 
Obstetric Formula : 
 
LMP  : 
EDD  : 
 
At Risk Factors : Big baby 
Hydramnios 
Multiple pregnancy 
Abruption 
Previous  History of  PPH 
Prolonged labour 
Grandmulti 
 
Onset of labour ; Spontaneous 
Induced –  ARM and oxytocin 
PGE2  gel without  oxytocin 
PGE 2 with  Oxytocin 
 
Duration of labour : First stage 
Second stage 
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Nature  of delivery : 
Management  of  third stage of labor:   Active management 
1.  Phylactic intravenous methyl ergometrine- 
     0.2mg 
    2.  Rectal  misoprostol-800 mcg 
Duration of  third stage : 
Amount of  blood loss : 
Complications  : PPH 
Retained placenta 
Others 
 
Any other drugs given : Ergot 
Oxytocin 
Inj. prostagladin 
 
Surgical intervention : Manual removal of placenta 
: Stepwise ligation 
Hysterectomy 
 
Blood  transfusion  : No. of units 
 
Side effects   :  
 
Outcome   : Maternal 
 
: Fetal 
 
Investigation   : 
 
Antenatal hemoglobin 
Postnatal hemoglobin 
Hemoglobin difference 
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GLOSSARY 
PPH  : Postpartum hemorrhage  
WHO  : World Health Organization 
PGE1  : Prostaglandin E1 
PGE2  : Prostaglandin E2 
PGF2 α : Prostaglandin F2 α 
ARM  : Artificial  rupture of membranes 
LN  : Labor naturale 
LP II°  : Perineal  Laceration II ° 
mcg  : Micro gram. 
mU/mt : Milliunits / minutes 
IV  : Intravenous  
IM  : Intramuscular  
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Examination of  the Placenta 
Brandt – Andrews Maneuver : Delivery of Placenta 
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Brandt – Andrews Maneuver : Delivery  of Placenta 
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Schultz  mechanism 
Duncan mechanism 
